Φορτώνει......
Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial
In this study, efficacy and safety of interferon (IFN) β-1b in the treatment of patients with severe COVID-19 were evaluated. Among an open-label, randomized clinical trial, adult patients (≥18 years old) with severe COVID-19 were randomly assigned (1:1) to the IFN group or the control group. Patien...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Int Immunopharmacol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Elsevier B.V.
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7445008/ https://ncbi.nlm.nih.gov/pubmed/32862111 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.intimp.2020.106903 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|